Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CVRx Inc (CVRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: CVRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 47.1% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 152.79M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 417688 | Beta 1.25 | 52 Weeks Range 4.30 - 18.55 | Updated Date 06/22/2025 |
52 Weeks Range 4.30 - 18.55 | Updated Date 06/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -97.49% | Operating Margin (TTM) -108.82% |
Management Effectiveness
Return on Assets (TTM) -26.88% | Return on Equity (TTM) -76.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 100280704 | Price to Sales(TTM) 2.89 |
Enterprise Value 100280704 | Price to Sales(TTM) 2.89 | ||
Enterprise Value to Revenue 1.9 | Enterprise Value to EBITDA -1.31 | Shares Outstanding 26072600 | Shares Floating 17884239 |
Shares Outstanding 26072600 | Shares Floating 17884239 | ||
Percent Insiders 4.26 | Percent Institutions 73.63 |
Analyst Ratings
Rating 4.57 | Target Price 16.83 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CVRx Inc
Company Overview
History and Background
CVRx, Inc. is a medical technology company founded in 2000, and focuses on developing, manufacturing, and marketing innovative neuromodulation solutions for patients with cardiovascular diseases. It has achieved milestones in treating heart failure and hypertension through its Barostim system.
Core Business Areas
- Neuromodulation Therapy: This segment focuses on developing and commercializing Barostim, a neuromodulation therapy designed to stimulate the baroreceptors in the carotid artery to treat heart failure and hypertension.
Leadership and Structure
CVRx is led by Nadim Yared as President and CEO. The company has a typical organizational structure for a medical device company, including departments for research and development, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Barostim System: Barostim is CVRx's flagship product, a neuromodulation device designed to treat heart failure and hypertension by stimulating baroreceptors. Market share data is not readily and publicly available. Competitors include companies offering alternative heart failure and hypertension treatments such as drug therapies (e.g., Novartis' Entresto) and other device-based therapies (e.g., Abbott's CardioMEMS).
Market Dynamics
Industry Overview
The medical device industry is characterized by technological innovation, strict regulatory requirements, and intense competition. The market for heart failure and hypertension treatments is large and growing due to the aging population and increasing prevalence of these conditions.
Positioning
CVRx is positioned as an innovator in neuromodulation therapy for cardiovascular diseases. Its competitive advantage lies in its proprietary Barostim technology and clinical evidence supporting its efficacy.
Total Addressable Market (TAM)
The TAM for heart failure and hypertension treatment is estimated to be significant, potentially in the billions of dollars annually. CVRx is positioned to capture a share of this market through the adoption of Barostim therapy. Estimates place the treatable market for Barostim at approximately 2 million patients.
Upturn SWOT Analysis
Strengths
- Innovative neuromodulation technology
- Clinical evidence supporting efficacy
- Proprietary Barostim system
- Focus on unmet needs in cardiovascular disease treatment
Weaknesses
- Limited market penetration to date
- High cost of therapy may limit adoption
- Reliance on a single primary product
- Requires specialized training for implantation and management
Opportunities
- Expanding indications for Barostim therapy
- Increasing awareness and adoption among physicians
- Partnerships with hospitals and healthcare systems
- Geographic expansion into new markets
Threats
- Competition from established therapies
- Reimbursement challenges from payers
- Technological advancements by competitors
- Adverse events or safety concerns
Competitors and Market Share
Key Competitors
- ABT
- BSX
- MDTC
Competitive Landscape
CVRx faces competition from established medical device companies with broader product portfolios and larger sales forces. Its competitive advantage lies in its innovative neuromodulation technology and focus on specific patient populations.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: CVRx's historical growth is dependent on the adoption of Barostim therapy and is subject to fluctuation based on the date range.
Future Projections: Future growth is predicted to rise with BAROSTIM, a chronic treatment therapy. Please refer to analyst reports for detailed financial projections.
Recent Initiatives: Recent initiatives include efforts to increase market penetration, expand clinical evidence, and secure favorable reimbursement coverage for Barostim therapy.
Summary
CVRx is an emerging player in the neuromodulation space with a focus on cardiovascular disease. The company's Barostim therapy holds promise for treating heart failure and hypertension, but its success depends on increasing market penetration and securing favorable reimbursement. Potential challenges include competition from established therapies and the need for specialized training. Strategic initiatives to expand clinical evidence and geographic reach will be crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- CVRx Investor Relations
- Company Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CVRx Inc
Exchange NASDAQ | Headquaters Minneapolis, MN, United States | ||
IPO Launch date 2021-06-30 | President, CEO & Director Mr. Kevin Hykes | ||
Sector Healthcare | Industry Medical Devices | Full time employees 206 | Website https://www.cvrx.com |
Full time employees 206 | Website https://www.cvrx.com | ||
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.